Most common investigator-reported* grade 3-4 adverse events with O-FC
| Adverse event, no. of patients (%) . | Ofatumumab 500 mg (n = 31) . | Ofatumumab 1000 mg (n = 30) . |
|---|---|---|
| Neutropenia | 11 (35) | 18 (60) |
| Thrombocytopenia | 2 (6) | 7 (23) |
| Anemia | 2 (6) | 6 (20) |
| Febrile neutropenia | 3 (10) | 3 (10) |
| Infections | 1 (3) | 4 (13) |
| Sepsis | 0 (0) | 2 (7) |
| Herpes virus | 1 (3) | 0 (0) |
| Respiratory | 0 (0) | 1 (3) |
| Unspecified | 0 (0) | 1 (3) |
| Adverse event, no. of patients (%) . | Ofatumumab 500 mg (n = 31) . | Ofatumumab 1000 mg (n = 30) . |
|---|---|---|
| Neutropenia | 11 (35) | 18 (60) |
| Thrombocytopenia | 2 (6) | 7 (23) |
| Anemia | 2 (6) | 6 (20) |
| Febrile neutropenia | 3 (10) | 3 (10) |
| Infections | 1 (3) | 4 (13) |
| Sepsis | 0 (0) | 2 (7) |
| Herpes virus | 1 (3) | 0 (0) |
| Respiratory | 0 (0) | 1 (3) |
| Unspecified | 0 (0) | 1 (3) |
Reported in ≥ 10% of patients in either dose cohort from start of treatment until 30 days following completion of treatment; grading by CTCAE Version 3.0.